Avidity Biosciences RNA
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Avidity Biosciences (RNA) Core Market Data and Business Metrics
Latest Closing Price
$29.77Price-Earnings Ratio
-10.30Total Outstanding Shares
120.21 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
10578 Science Center Drive, San Diego, CA, 92121
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,283,034 Shares | 12.57 | 3/14/2025 | 16,128,099 Shares |
| 1,264,375 Shares | 13.41 | 2/28/2025 | 16,954,734 Shares |
| 1,448,815 Shares | 11.38 | 2/14/2025 | 16,480,495 Shares |
| 1,246,050 Shares | 12 | 1/31/2025 | 14,949,939 Shares |
| 1,361,836 Shares | 11.3 | 1/15/2025 | 15,389,142 Shares |
| 1,416,793 Shares | 11.07 | 12/31/2024 | 15,684,175 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $1.21 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-738.99 Million |
| Net Cash Flow, Continuing | $287.04 Million |
| Net Cash Flow From Financing Activities, Continuing | $1.21 Billion |
| Net Cash Flow From Operating Activities, Continuing | $-184.50 Million |
| Net Cash Flow From Investing Activities | $-738.99 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $-2.89 |
| Other Operating Expenses | $74.02 Million |
| Net Income/Loss Attributable To Parent | $-280.49 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Benefits Costs and Expenses | $290.61 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-271.51 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $8.98 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-271.51 Million |
| Other Comprehensive Income/Loss | $-71.42 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Non-current Assets | $9.41 Million |
| Prepaid Expenses | $14.06 Million |
| Current Liabilities | $91.33 Million |
| Liabilities | $137.39 Million |
| Fixed Assets | $9.49 Million |
| Noncurrent Assets | $18.91 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||